China Shineway Pharmaceutical : TURNOVER FOR THE FIRST QUARTER OF 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

TURNOVER FOR THE FIRST QUARTER OF 2021

The board of directors (the "Board") of China Shineway Pharmaceutical Group Limited (the "Company") is pleased to announce that, the turnover of the Company and its subsidiaries (together, the "Group") for the three months ended 31 March 2021 ("the First Quarter of 2021") based on its management accounts which have not been reviewed by the auditors, reached RMB744,000,000, representing an increase of

37.0% as compared with the same quarter of 2020, and in particular:

• Turnover of injection products increased by 34.2% to RMB306,000,000;
• Turnover of soft capsule products increased by 6.6% to RMB113,000,000;
• Turnover of granule products increased by 62.2% to RMB133,000,000;
• Turnover of TCM formula granule products increased by 50.5% to RMB155,000,000; and
• Turnover of products in other forms increased by 54.2% to RMB37,000,000.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 41.1%, 15.2%, 17.9% and 20.8% of the total turnover respectively for the First Quarter of 2021.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board

China Shineway Pharmaceutical Group Limited

Li Zhenjiang

Chairman

Hong Kong, 6 May 2021

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Cheung Chun Yue Anthony.